Table 2.
Patients characteristics and univariate analysis of c-SCLC (N = 31)
| Characteristics | n (%) | PFS | OS | ||
|---|---|---|---|---|---|
| Median (95% CI) | p value | Median (95% CI) | p value | ||
| Gender | 0.036* | 0.249 | |||
| Male | 26 (83.9) | _a | 75.0 (34.6–115.4) | ||
| Female | 5 (16.1) | 4.0 (0.0–8.3) | 34.0 (21.1–46.9) | ||
| Age(year) | 0.681 | 0.455 | |||
| ≤ 62 | 15 (48.4) | 18.0 | 91.0 (61.2–120.8) | ||
| > 62 | 16 (51.6) | _a | 37.0 (0.0–77.3) | ||
| Smoking history | 0.043* | 0.041* | |||
| Absence | 9 (29.0) | _a | _a | ||
| Presence | 22 (71.0) | 11.0 (0.0–24.5) | 53.0 (18.0–88.0) | ||
| Tumor location | 0.048* | 0.073 | |||
| Central | 8 (25.8) | _a | 26.0 (13.5–38.5) | ||
| Peripheral | 23 (74.2) | 6.0 (2.3–9.7) | 91.0 (50.3–131.7) | ||
| SUVmax | 0.084 | 0.040* | |||
| ≤ 9 | 16 (51.6) | _a | 96.0 (84.8–107.2) | ||
| > 9 | 15 (48.4) | 8.0 (0.0–17.2) | 37.0 (10.7–63.3) | ||
| MTV | 0.272 | 0.347 | |||
| ≤ 10.35 | 16 (51.6) | 18.0 | 75.0 (17.7–132.3) | ||
| > 10.35 | 10 (32.3) | _a | _a | ||
| TLG | 0.552 | 0.793 | |||
| ≤ 128.23 | 20 (64.5) | _a | 91.0 (70.0–112.0) | ||
| > 128.23 | 6 (19.4) | _a | 37.0 | ||
| Mixed component | 0.072 | 0.083 | |||
| SCC | 12 (38.7) | 6.0 (0.0–12.2) | 28.0 (16.1–39.9) | ||
| AC | 6 (19.4) | _a | _a | ||
| LCC | 7 (22.6) | _a | _a | ||
| Spindle cell | 4 (12.9) | 5.0 (0.0–13.8) | 34.0 (9.5–58.5) | ||
| Others | 2 (6.5) | ||||
| Mixed Component | 0.086 | 0.029* | |||
| SCC | 12 (38.7) | 6.0 (0.0–12.2) | 28.0 (16.1–39.9) | ||
| Non-SCC | 19 (61.3) | _a | 100.0 (75.3–124.7) | ||
| Tumor size | 0.055 | 0.046* | |||
| ≤ 3 cm | 20 (64.5) | 11.0 (0.0–23.8) | 53.0 (0.4–105.6) | ||
| > 3 cm | 11 (35.5) | _a | _a | ||
| TNM stage | 0.068 | 0.365 | |||
| I | 13 (41.9) | 54.0 | 60.0 (27.3–92.7) | ||
| II | 8 (25.8) | 96.0 (65.0–127.0) | |||
| III | 10 (32.3) | 4.0 (0.9–7.1) | 33.0 (20.6–45.4) | ||
| Radiotherapy | 0.292 | 0.815 | |||
| Yes | 11 (35.5) | 8.0 (0.0–60.9) | 75.0 (20.1–129.9) | ||
| No | 20 (64.5) | _a | 91.0 (14.5–167.5) | ||
| Chemotherapy | 0.085 | 0.630 | |||
| Yes | 26 (83.9) | _a | 75.0 (35.0–115.0) | ||
| No | 5 (16.1) | _a | _a | ||
| Surgical approach | 0.659 | 0.700 | |||
| Thoracotomy | 24 (77.4) | 11.0 | 75.0 (11.8–138.2) | ||
| VATS | 7 (22.6) | 54.0 | 60.0 (45.6–74.4) | ||
| Type of resection | 0.496 | 0.501 | |||
| Lobectomy | 21 (67.7) | _a | 91.0 (26.9–155.1) | ||
| Bilobectomy | 3 (9.7) | _a | _a | ||
| Pneumonectomy | 3 (9.7) | 8.0 (4.8–11.2) | 75.0 (0–169.4) | ||
| Wedge resection | 4 (12.9) | 2.0 | 28.0 (0–69.2) | ||
| NSE | 0.179 | 0.543 | |||
| ≤ 15 ug/L | 17 (63.0) | _a | 60.0 (31.9–88.1) | ||
| > 15 ug/L | 10 (37.0) | 6.0 (0.0–14.2) | 34.0 (29.4–38.6) | ||
| CEA | 0.658 | 0.147 | |||
| ≤ 5 ug/L | 22 (81.5) | 18.0 | 75.0 (38.5–111.5) | ||
| > 5 ug/L | 5 (18.5) | 54.0 (0.0–130.3) | 36.0 (18.8–53.2) | ||
| HGB | 0.545 | 0.464 | |||
| ≤ 138.5 | 15(50.0) | _a | 96.0 (10.8–181.2) | ||
| > 138.5 | 15 (50.0) | 18.0 (0.0–79.3) | 60.0 (24.0–96.0) | ||
| NLR | 0.951 | 0.684 | |||
| ≤ 2.24 | 15 (50.0) | 54.0 (0.0–126.9) | 75.0 (41.0–109.0) | ||
| > 2.24 | 15 (50.0) | _a | 37.0 (0.0–92.0) | ||
| PLR | 0.504 | 0.604 | |||
| ≤ 121.9 | 15 (50.0) | 54.0 | 60.0 (31.2–88.8) | ||
| > 121.9 | 15 (50.0) | 11.0 | 91.0 (0.0–183.1) | ||
PFS progression-free survival; OS overall survival; CI confidence interval; SUVmax maximum standardized uptake value; MTV metabolic tumor volume; TLG total lesion glycolysis; SCC squamous cell carcinoma; AC adenocarcinoma; LCC large-cell carcinoma; TNM tumor–node–metastasis; VATS video-assisted thoracoscopic surgery; NSE neuron specific enolase; CEA carcinoembryonic antigen; HGB hemoglobin; NLR neutrophil–lymphocyte ratio; PLR platelet–lymphocyte ratio
*Significantly different
−a Median survival could not be estimated because more than half of the patients in the corresponding subgroup are alive